- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07426419
En AAV-geneterapistudie av AFTX-201 for voksne med BAG3-assosiert dilatert kardiomyopati (DCM) (UPBEAT)
En fase 1/2 multicenter, åpen merket, dose-eskalering og dose-ekspansjonsstudie for å vurdere sikkerhet, tolerabilitet, farmakodynamikk og foreløpig effekt av AFTX-201 gitt til voksne deltakere med BCL2-assosiert atanogen 3 (BAG3) mutasjon-assosiert dilatert kardiomyopati: UPBEAT-studien
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Participants will receive a single intravenous infusion of AFTX-201 and will be followed for safety and clinical assessments. The study includes short-term safety monitoring and long-term follow-up for up to 60 months
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Information
- Telefonnummer: 2 (617) 430-7817
- E-post: clinicaltrials@affiniatx.com
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, QC H1T 1C8
- Rekruttering
- Institut de Cardiologie de Montréal / Montreal Heart Institute
-
Ta kontakt med:
- Jérémie Coordonnateur de recherche EPS / EP research coordinator, BScN
- Telefonnummer: 2293 514-376-3330
- E-post: Jeremie.Cortial@icm-mhi.org
-
Hovedetterforsker:
- Rafik Tadros, MD
-
-
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Hospital and Clinics
-
Ta kontakt med:
- Lina Carceres
- Telefonnummer: 954 249 3587
- E-post: caceresl@miami.edu
-
Hovedetterforsker:
- Joshua Hare, MD
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Rekruttering
- St. Lukes Hospital
-
Hovedetterforsker:
- Andrew Kao, MD
-
Ta kontakt med:
- Amanda Huffman, RN, BSN
- Telefonnummer: 816-932-0391
- E-post: amanda.huffman@bjc.org
-
-
New York
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Langone
-
Hovedetterforsker:
- Tajinderpal Saraon, MD
-
Ta kontakt med:
- Loriya Thao
- Telefonnummer: 646-877-6343
- E-post: loriya.thao@nyulangone.org
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Hovedetterforsker:
- Cindy Martin, MD
-
Ta kontakt med:
- Jennifer (Garrett) Medley Sr. Clinical Trials Manager
- Telefonnummer: 346-238-4516
- E-post: jmgarrett@houstonmethodist.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Male or female, 18 to 70 years of age
Truncating mutation in BAG3
Dilated cardiomyopathy with left ventricular ejection fraction (LVEF) < 50% by echocardiogram or cardiac MRI
NYHA Class II or III heart failure symptoms
Body weight ≤ 120 kg
Willing and able to sign informed consent and comply with study procedures
Exclusion Criteria:
Prior myocardial infarction when, in the investigator's judgment, the totality of clinical and imaging evidence supports that left ventricular dysfunction is due to coronary artery disease rather than BAG3-associated dilated cardiomyopathy
Prior heart transplant
Presence or requirement of a left ventricular assist device (LVAD)
IV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment
Positive neutralizing antibodies to ATC-0187
Any condition that, in the investigator's opinion, would place the subject at undue risk or interfere with study participation or interpretation of results
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: AFTX-201
Participants will receive a single intravenous dose of AFTX-201 |
AFTX-201 is a gene therapy product consisting of the ATC-0187 capsid containing the BCL2-associated Athanogene 3 (BAG3) transgene. It is administered as a single intravenous infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Tidsramme: Baseline through 12 months
|
Safety and tolerability of AFTX-201 over 12 months. |
Baseline through 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in pharmacodynamic biomarkers
Tidsramme: Baseline through 12 months
|
Assessment of the extent of AFTX-201 transduction and myocardial BAG3 protein expression after a single IV dose |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including left ventricular ejection fraction (LVEF)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including peak oxygen consumption (pVO2) by cardiopulmonary exercise test (CPET)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in New York Heart Association (NYHA) functional class
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on features of heart failure (HF) including functional classification by New York Heart Association (NYHA) class |
Baseline through 12 months
|
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Tidsramme: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on quality of life |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels through 12 months
Tidsramme: Baseline through 12 months
|
Assessment of the change from baseline in NT-proBNP levels following a single intravenous dose of AFTX-201 |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels during long-term follow-up
Tidsramme: Baseline through 60 months
|
Assessment of the change from baseline in NT-proBNP levels during long-term follow-up following a single intravenous dose of AFTX-201 |
Baseline through 60 months
|
|
Number of participants with adverse events during long-term follow-up
Tidsramme: Baseline through 60 months
|
Safety and tolerability of AFTX-201 over 60 months |
Baseline through 60 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AFTX-201-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .